Evommune EVMN
NYSE EVMN
$8.31 -0.08 (-0.95%)
As of: Sep 29, 2026 · 3:59 PM EDT

Evommune (EVMN) Capital Leases (2024 - 2026)

Updated

Evommune's Capital Leases was $434,000 in Q2 2026, down 18.0% from the prior quarter.

Analysis

Evommune (EVMN) Capital Leases (2024 - 2026) Analysis & Trends

At the end of FY2025, Capital Leases at Evommune came in at $181,000, down 66.2% from FY2024.

  • In earlier years, Capital Leases was $535,000 in FY2024.
  • Quarterly Capital Leases has moved between $181,000 (Q4 2025) and $535,000 (Q4 2024) over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Evommune 304.40 Mn -333.11 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 434,000.00
Mar 31, 2026 529,000.00
Dec 31, 2025 181,000.00
Dec 31, 2024 535,000.00
API Access

Evommune Capital Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-leases&ticker=EVMN&period=max&api_key=YOUR_API_KEY